(firstQuint)A Study of LY2584702 With Erlotinib or Everolimus in Patients With Solid Tumors.

 Study JGCB will consist of the following parts: Part 1 - Dose Escalation to maximum tolerated dose in each arm.

 Arm A - LY2584702 + Erlotinib in patients with advanced or metastatic cancer.

 Arm B - LY2584702 + Everolimus in patients with advanced or metastatic cancer.

 Part 2 - Dose Confirmation of maximum tolerated dose from each arm in Part 1.

 Arm A - LY2584702 + Erlotinib in patients with advanced or metastatic non-small cell lung cancer.

 Arm B - LY2584702 + Everolimus in patients with advanced renal cell carcinoma after treatment failure with sunitinib or sorafenib, or advanced neuroendocrine tumors.

.

 A Study of LY2584702 With Erlotinib or Everolimus in Patients With Solid Tumors@highlight

Study JGCB is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.

